Questcor Pharmaceuticals Inc  

(Public, NASDAQ:QCOR)   Watch this stock  
Find more results for Raymond Stephens
-1.51 (-1.92%)
Apr 17 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 76.60 - 78.50
52 week 27.40 - 85.69
Open 77.94
Vol / Avg. 0.00/3.28M
Mkt cap 4.66B
P/E 16.28
Div/yield 0.30/1.56
EPS 4.73
Shares 60.58M
Beta 0.73
Inst. own 105%
Apr 28, 2014
Q1 2014 Questcor Pharmaceuticals, Inc. Earnings Release (Estimated) Add to calendar
Feb 25, 2014
Q4 2013 Questcor Pharmaceuticals, Inc. Earnings Conference Call
Feb 25, 2014
Q4 2013 Questcor Pharmaceuticals, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 37.05% 36.63%
Operating margin 56.13% 55.05%
EBITD margin - 56.92%
Return on average assets 50.55% 59.19%
Return on average equity 92.05% 104.28%
Employees 324 -
CDP Score - -


Suite D, 1300 North Kellogg Drive
United States - Map
+1-714-7864200 (Phone)
+1-714-7894229 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Questcor Pharmaceuticals, Inc. (Questcor) is a biopharmaceutical company. The Company is focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders. Its primary product is H.P. Acthar Gel (repository corticotropin injection), or Acthar, an injectable drug that is approved by the United States food and drug administration (FDA), for the treatment of 19 indications. Its research and development program is focused on: the evaluation of the use of Acthar for certain on-label indications; the investigation of other potential uses of Acthar for indications not FDA approved; and the expansion of its understanding of how Acthar works in the human body (pharmacology), and ultimately, its mechanisms of action in the disease states for which it is used, or may be used in the future. The Company sells Doral to pharmaceutical wholesalers, which resell Doral primarily to retail pharmacies and hospitals.

Officers and directors

Virgil D. Thompson Independent Chairman of the Board
Age: 73
Bio & Compensation  - Reuters
Don M. Bailey President, Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Rajesh Asarpota Chief Financial Officer, Senior Vice President
Age: 47
Bio & Compensation  - Reuters
Stephen L. Cartt Chief Operating Officer
Age: 50
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
David J. Medeiros Executive Vice President, Chief Technical Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael H. Mulroy Executive Vice President - Strategic Affairs, General Counsel
Age: 47
Bio & Compensation  - Reuters
Raymond J. Furey Senior Vice President, Chief Compliance Officer
Age: 45
Bio & Compensation  - Reuters
David Young Ph.D. Chief Scientific Officer
Age: 60
Bio & Compensation  - Reuters
Neal C. Bradsher Independent Director
Age: 47
Bio & Compensation  - Reuters
Stephen C. Farrell CPA Independent Director
Age: 47
Bio & Compensation  - Reuters